Jubilant Pharmova Share Price
Jubilant Pharmova Share Price Today
As of 25 Jul 2026, Jubilant Pharmova share price is ₹969.00. The stock opened at ₹960.20, compared to its previous close of ₹970.80. During today's trading session, Jubilant Pharmova share price moved in the range of ₹950.60 to ₹971.10, with an average price of ₹960.85 for the day. Looking at its last 52-week, the stock has touched a low of ₹786.05 and a high of ₹1,248.00. On the performance front, Jubilant Pharmova share price has increased by 0.97% over the last six months and is down 17.84% on a year-on-year basis.
Jubilant Pharmova Returns Calculator
Jubilant Pharmova Shareholder Returns
Jubilant Pharmova Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,65,711.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,93,860.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,92,687.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,12,593.00 | 33.55 | 3.27 | 11.27% | 0.00 | 14.95% | 423.36 | 0.93% | 0.44 | 43.52 |
| Zydus Lifesciences | 1,11,082.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,09,553.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,05,607.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 97,364.90 | 30.58 | 2.56 | 11.07% | 0.18 | 12.54% | 377.96 | 0.69% | 0.41 | 38.68 |
| Aurobindo Pharma | 88,508.40 | 25.27 | 2.34 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 84,727.30 | 60.26 | 10.10 | 18.21% | 0.40 | 16.70% | 97.21 | 0.12% | 0.64 | 13.72 |
Jubilant Pharmova Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹7,234.50 | ₹6,702.90 | ₹6,281.70 | ₹6,130.16 |
| Other Income | ₹56.80 | ₹68.70 | ₹38.30 | ₹11.29 |
| Total Revenue | ₹7,291.30 | ₹6,771.60 | ₹6,320.00 | ₹6,141.45 |
| Total Expenses | ₹6,669.70 | ₹6,456.30 | ₹6,247.70 | ₹5,501.02 |
| Profit Before Tax | ₹980.60 | ₹170.50 | ₹27.80 | ₹630.45 |
| Tax | ₹144.30 | ₹97.80 | ₹92.70 | ₹217.43 |
| Profit After Tax | ₹836.30 | ₹72.70 | -₹64.90 | ₹413.02 |
| EPS - Basic | ₹52.99 | ₹4.87 | -₹3.83 | ₹26.00 |
| EPS - Diluted | ₹52.85 | ₹4.86 | -₹3.83 | ₹26.00 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹980.60 | ₹170.50 | ₹27.80 | ₹630.45 |
| Income before WC changes | ₹1,198.70 | ₹925.90 | ₹810.70 | ₹1,209.92 |
| Change in Assets | ₹73.50 | ₹197.00 | ₹118.00 | -₹135.57 |
| Change in Liabilities | ₹38.30 | ₹56.10 | -₹63.70 | -₹42.71 |
| Change in WC | ₹111.80 | ₹253.10 | ₹54.30 | -₹178.29 |
| Cash flow from Operations | ₹1,072.10 | ₹971.30 | ₹660.70 | ₹837.54 |
| Cash flow from Investing | ₹487.70 | -₹607.90 | -₹544.40 | -₹380.37 |
| Cash flow from Financing | -₹1,452.70 | -₹432.50 | -₹156.70 | -₹32.60 |
| Total Cash Flow | ₹131.90 | -₹57.50 | ₹30.10 | ₹481.86 |
| Cash (Start of the year) | ₹956.40 | ₹1,013.90 | ₹983.80 | ₹501.96 |
| Cash (End of the year) | ₹1,088.30 | ₹956.40 | ₹1,013.90 | ₹983.82 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹9,179.20 | ₹7,672.40 | ₹7,394.30 | ₹6,481.68 |
| Current Assets | ₹3,577.20 | ₹3,876.10 | ₹3,762.40 | ₹3,509.19 |
| Total Assets | ₹12,756.40 | ₹11,548.50 | ₹11,156.70 | ₹9,990.87 |
| Current Liabilities | ₹2,164.60 | ₹1,889.00 | ₹1,772.40 | ₹1,591.60 |
| Net Current Asset | ₹1,412.60 | ₹1,987.10 | ₹1,990.00 | ₹1,917.59 |
| Non-Current Liabilities | ₹4,353.20 | ₹4,238.40 | ₹3,992.50 | ₹3,082.87 |
| Equity Capital | ₹6,238.60 | ₹5,421.10 | ₹5,391.80 | ₹5,316.40 |
| Total Equity & Liabilities | ₹12,756.40 | ₹11,548.50 | ₹11,156.70 | ₹9,990.87 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹745.70 | ₹784.70 | ₹810.10 | ₹725.73 |
| Other Income | ₹99.60 | ₹103.40 | ₹137.90 | ₹126.16 |
| Total Revenue | ₹845.30 | ₹888.10 | ₹948.00 | ₹851.89 |
| Total Expenses | ₹796.50 | ₹846.40 | ₹868.70 | ₹767.17 |
| Profit Before Tax | ₹37.60 | ₹41.70 | ₹79.30 | ₹84.72 |
| Tax | ₹18.40 | ₹10.10 | ₹29.40 | ₹4.23 |
| Profit After Tax | ₹19.20 | ₹31.60 | ₹49.90 | ₹80.49 |
| EPS - Basic | ₹1.21 | ₹1.99 | ₹3.13 | ₹5.05 |
| EPS - Diluted | ₹1.21 | ₹1.99 | ₹3.13 | ₹5.05 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹37.60 | ₹41.70 | ₹79.30 | ₹84.72 |
| Income before WC changes | ₹116.80 | ₹89.90 | ₹44.10 | ₹36.04 |
| Change in Assets | ₹24.30 | ₹71.50 | -₹55.90 | -₹57.39 |
| Change in Liabilities | ₹7.00 | -₹6.00 | -₹35.90 | ₹53.97 |
| Change in WC | ₹31.30 | ₹65.50 | -₹91.80 | -₹3.42 |
| Cash flow from Operations | ₹135.60 | ₹143.20 | -₹65.10 | -₹3.55 |
| Cash flow from Investing | -₹2.30 | -₹40.30 | ₹31.10 | ₹93.10 |
| Cash flow from Financing | -₹156.80 | -₹77.80 | ₹22.50 | -₹107.37 |
| Total Cash Flow | -₹23.50 | ₹25.10 | -₹11.50 | -₹17.82 |
| Cash (Start of the year) | ₹36.10 | ₹11.00 | ₹22.50 | ₹40.35 |
| Cash (End of the year) | ₹12.60 | ₹36.10 | ₹11.00 | ₹22.53 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹2,425.40 | ₹2,451.30 | ₹2,429.60 | ₹2,369.75 |
| Current Assets | ₹484.20 | ₹540.60 | ₹578.80 | ₹525.81 |
| Total Assets | ₹2,909.60 | ₹2,991.90 | ₹3,008.40 | ₹2,895.56 |
| Current Liabilities | ₹310.30 | ₹315.40 | ₹361.20 | ₹252.26 |
| Net Current Asset | ₹173.90 | ₹225.20 | ₹217.60 | ₹273.55 |
| Non-Current Liabilities | ₹281.20 | ₹302.00 | ₹232.70 | ₹204.23 |
| Equity Capital | ₹2,318.10 | ₹2,374.50 | ₹2,414.50 | ₹2,439.07 |
| Total Equity & Liabilities | ₹2,909.60 | ₹2,991.90 | ₹3,008.40 | ₹2,895.56 |
About Jubilant Pharmova
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
Jubilant Pharmova Financial Highlights
- Revenue: Jubilant Pharmova reported revenue of ₹8,345.60 crore in FY26 vs ₹7,291.30 crore in FY25. It showed an increase of 14.46% on a yearly basis.
- Operating Profit: Jubilant Pharmova reported an operating profit of ₹614.10 crore in FY26 vs ₹980.60 crore in FY25. It showed a decrease of 37.38% on a year-on-year basis.
- Net Profit: Jubilant Pharmova reported a net profit of ₹397.50 crore in FY26 vs ₹836.30 crore in FY25. It showed a decrease of 52.47% on a yearly basis.
Jubilant Pharmova Quarterly Result Highlights
- Jubilant Pharmova reported revenue of ₹2,313.70 crore in Mar 2026, compared with ₹2,143.00 crore in Dec 2025, representing an increase of 7.97% on a quarter-on-quarter (QoQ) basis.
- Jubilant Pharmova reported an operating profit of ₹176.00 crore in Mar 2026, compared with ₹93.40 crore in Dec 2025, representing an increase of 88.44% on a quarter-on-quarter (QoQ) basis.
- Jubilant Pharmova reported a profit of ₹119.30 crore in Mar 2026, compared with ₹55.80 crore in Dec 2025, reflecting an increase of 113.80% on a QoQ basis.
- The earnings per share (EPS) of Jubilant Pharmova stood at ₹52.99 during Mar 2026.
Similar Stocks
FAQs on Jubilant Pharmova Share Price
What is Jubilant Pharmova share price today?
Jubilant Pharmova share price is ₹969.00 as on 24 Jul, 2026, 15:29 IST.
How has the Jubilant Pharmova share price performed in the past?
In the last 1 year, Jubilant Pharmova delivered a return of -17.84%. The Jubilant Pharmova share price hit a high of ₹1,248.00 and low of ₹786.05.
How much is the Mutual Fund shareholding in Jubilant Pharmova shares?
The Mutual Fund Shareholding in Jubilant Pharmova was 8.99% at the end of Jun 2026.
What is the the 52-week high and low of Jubilant Pharmova shares ?
The 52-week high and low of Jubilant Pharmova share is ₹1,248.00 and ₹786.05 as of 24 Jul, 2026.
What is the market cap of Jubilant Pharmova?
The market capitalisation of Jubilant Pharmova is ₹15,465.60 Crores as on 24 Jul, 2026.
What are the stock symbols of Jubilant Pharmova?
The stock symbol of Jubilant Pharmova is JUBLPHARMA on the NSE, 530019 on the BSE, and the ISIN is INE700A01033.
What was yesterday's closing price of Jubilant Pharmova shares ?
Jubilant Pharmova shares closed yesterday at ₹970.80 on NSE & ₹970.85 on BSE
How to buy Jubilant Pharmova shares?
To buy Jubilant Pharmova shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Jubilant Pharmova shares on Holidays?
No, shares of Jubilant Pharmova or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Jubilant Pharmova shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Jubilant Pharmova?
The PE and PB ratio of Jubilant Pharmova is 38.91 and 2.18 respectively, as on 24 Jul, 2026, 15:29 IST.